|
|
|
| Effects of Shenmai Injection on Inflammatory Markers, Cardiac Function and Prognosis of Acute Coronary Syndrome After PCI |
| ZHOU Linghua, JING Xiumei, GU Yongmei, et al |
| Hai'an Hospital Affiliated to Nantong University, Jiangsu Haian 226600, China |
|
|
|
|
Abstract Objective: To explore the effect of using Shenmai injection as an adjuvant therapy in patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI). Methods: In recent years, 84 ACS patients having undergoing PCI were randomly divided into two groups. The control group was given standardized treatment with western medicine, and the observation group was treated with Shenmai injection. Changes in inflammation, cardiac markers and cardiac function indicators, rates of cardiovascular adverse events and adverse drug reactions were observed. Results:After 2 weeks of treatment, hypersensitive c-reactive protein (hs-crp), endothelin-1 (et-1) and D- were detected in the observation group- D dimer (D) inflammatory indicators, such as superoxide dismutase (SOD), creatine kinase isoenzyme (CK - MB) and troponin -i cardiac markers, such as (cTn - I) levels, and each cardiac output (SV), left ventricular ejection fraction (LVEF), ventricular wall motion index (WMSI) and Seattle angina questionnaire (SAQ) score indicators, improved significantly, compared with the control group (P < 0.05). The rate of adverse cardiovascular events in the observation group was significantly lower than that in the control group (P < 0.05), and there was no difference in the rate of adverse drug reactions between the groups (P > 0.05). Conclusion: The adjuvant therapy of Shenmai injection for ACS patients undergoing PCI can inhibit the inflammatory response of the body, improve the level of cardiac markers, improve the cardiac function, improve the prognosis of the disease, and improve the drug safety.
|
|
|
|
|
|
[1] 王昊,朱成刚,宁晓晖,等.合并多血管疾病冠心病患者经皮冠状动脉介入治疗长期预后的研究[J].中国循环杂志,2019,34(9):866~871.
[2] 何传飞,纪勤炯,张陵,等.研究参麦联合欣维宁对急性心肌梗死介入后心脏结构和功能的影响[J].临床急诊杂志,2016,17(9):671~674.
[3] 冯小智,刁杰,方婷,等.中医辨证治疗对行介入疗法的急性心肌梗死患者心肌再灌注和心功能的改善作用[J].中华中医药学刊,2018,36(11):2760~2763.
[4] 周海芳,叶远玲,王瑞明.参麦注射液联合美罗培南对老年重症感染患者细胞免疫功能、炎症因子及肺功能的影响[J].中国老年学杂志,2018,38(8):1885~1887.
[5] 任玉军.左卡尼汀联合参麦注射液对慢性肺源性心脏病合并心力衰竭患者心功能的影响[J].河北医学,2016,22(12):2063~2065.
[6] 刘小芳.参麦注射液治疗急性肺损伤的疗效及对血清ICAM-1、ET-1及NO的影响[J].现代中西医结合杂志,2017,26(25):2784~2786.
[7] 吕燕妮,付龙生,彭洪薇,等.参麦注射剂对H2O2诱导PC12细胞氧化损伤的保护作用及机制[J].中国临床药学杂志,2016,25(2):77~81.
[8] 黎清华,邓行,周晓燕,等.参麦注射液对急性心肌梗死患者急诊PCI术后心肌的影响[J].河南中医,2016,36(3):430~433.
[9] 周秋秋,任谓明,王艳红,等.红参的炮制、化学成分及药理活性研究进展[J].上海中医药杂志,2016,50(2):97~100.
[10] 许祖建,戴小华,汤丽芬,等.对冠心病PCI术后患者心功能及心绞痛疗效的影响[J].时珍国医国药,2019,30(9):2208~2209.
[11] 徐晓娟.参麦注射液联合氯吡格雷治疗急性心肌梗死的临床效果及对心功能的影响[J].广西医科大学学报,2018,35(2):255~257. |
|
|
|
2020, Vol. 26 
